Targeting histone methylation to reprogram the transcriptional state that drives survival of drug-tolerant myeloid leukemia persisters
Noortje van Gils, Han Verhagen, Michaël Broux, Tània Martiáñez, Fedor Denkers, Eline Vermue, Arjo Rutten, Tamás Csikós, Sofie Demeyer, Meryem Çil, Marjon Al, Jan Cools, Jeroen J. W. M. Janssen, Gert J. Ossenkoppele, Renée X. de Menezes, Linda Smit
Abstract
. Our results reveal plasticity of anthracycline resistance in AML cells and highlight the potential of transcriptional reprogramming by epigenetic-based therapeutics to target chemotherapy-resistant AML cells.
Topics & Concepts
ReprogrammingMyeloid leukemiaCancer researchBiologyLeukemiaH3K4me3DoxorubicinEpigeneticsAnthracyclineStem cellDaunorubicinPopulationEpigenetic therapyChemotherapyDNA methylationImmunologyMedicineCellCell biologyCancerGeneticsPromoterGene expressionGeneBreast cancerEnvironmental healthAcute Myeloid Leukemia ResearchEpigenetics and DNA MethylationHistone Deacetylase Inhibitors Research